The BINSA Act amends the Defense Production Act to redefine biotechnology and enhance national security protections.
The BINSA Act amends the Defense Production Act of 1950 to redefine "biotechnology" to include pharmaceutical products, biological products, and therapeutic compounds. It also adds licensing transactions as a category for both prohibited and notifiable technology. The Act requires the Secretary of Defense to submit a report on the impact of U.S. capital flows into China's biotechnology sector on national security. The Secretary of the Treasury must issue a rule to further define biotechnology parameters, excluding agricultural biotechnology and basic academic research.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.